Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in asian patients

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 2, 2011, Pages 130-136

  Singh, Onkar ^a   Sandanaraj, Edwin ^a   Subramanian, Koilan ^a   Lee, Lai Heng ^b   Chowbay, Balram ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Asian; CYP4F2; Pharmacogenetics; Polymorphism; Warfarin

Indexed keywords

OMEPRAZOLE; SIMVASTATIN; WARFARIN;

ADULT; AFRICAN AMERICAN; AGED; ANTICOAGULANT THERAPY; ARTICLE; ASIAN; CONTROLLED STUDY; CYTOCHROME P450 2C9 GENE; CYTOCHROME P450 4F2 GENE; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; ETHNIC DIFFERENCE; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PROSTHETIC VALVE THROMBOSIS; PROTEIN EXPRESSION; THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1 GENE;

EID: 79955711867     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RG-080     Document Type: Article

References (39)

1. Anand, S. S. and Yusuf, S.: Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA, 282: 2058-2067 (1999).
2. Beyth, R. J., Milligan, P. E. and Gage, B. F.: Risk factors for bleeding in patients taking coumarins. Curr. Hematol. Rep., 1: 41-49 (2002).
3. Wells, P. S., Holbrook, A. M., Crowther, N. R. and Hirsh, J.: Interactions of warfarin with drugs and food. Ann. Intern. Med., 121: 676-683 (1994).
4. Kamali, F., Khan, T. I., King, B. P., Frearson, R., Kesteven, P., Wood, P., Daly, A. K. and Wynne, H.: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther., 75: 204-212 (2004).
5. Absher, R. K., Moore, M. E. and Parker, M. H.: Patient-specific factors predictive of warfarin dosage requirements. Ann. Pharmacother., 36: 1512-1517 (2002).
6. Gan, G. G., Teh, A., Goh, K. Y., Chong, H. T. and Pang, K. W.: Racial background is a determinant factor in the maintenance dosage of warfarin. Int. J. Hematol., 78: 84-86 (2003).
7. Scordo, M. G., Pengo, V., Spina, E., Dahl, M. L., Gusella, M. and Padrini, R.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther., 72: 702-710 (2002).
8. Breckenridge, A., Orme, M., Wesseling, H., Lewis, R. J. and Gibbons, R.: Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther., 15: 424-430 (1974).
9. Takahashi, H. and Echizen, H.: Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet., 40: 587-603 (2001).
10. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J. and Trager, W. F.: Hydroxylation of warfarin by human cDNAexpressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol., 5: 54-59 (1992).
11. Ngui, J. S., Chen, Q., Shou, M., Wang, R. W., Stearns, R. A., Baillie, T. A. and Tang, W.: In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4$- and 10- hydroxywarfarin. Drug Metab. Dispos., 29: 877-886 (2001).
12. Zhang, Z., Fasco, M. J., Huang, Z., Guengerich, F. P. and Kaminsky, L. S.: Human cytochromes P4501A1 and P4501A2: Rwarfarin metabolism as a probe. Drug Metab. Dispos., 23: 1339-1346 (1995).
13. Wienkers, L. C., Wurden, C. J., Storch, E., Kunze, K. L., Rettie, A. E. and Trager, W. F.: Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)- mephenytoin hydroxylase, P4502C19. Drug Metab. Dispos., 24: 610-614 (1996).
14. Li, T., Chang, C. Y., Jin, D. Y., Lin, P. J., Khvorova, A. and Stafford, D. W.: Identification of the gene for vitamin K epoxide reductase. Nature, 427: 541-544 (2004).
15. Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H. J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., Müller, C. R., Strom, T. M. and Oldenburg, J.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature, 427: 537-541 (2004).
16. Takahashi, H., Kashima, T., Nomizo, Y., Muramoto, N., Shimizu, T., Nasu, K., Kubota, T., Kimura, S. and Echizen, H.: Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin. Pharmacol. Ther., 63: 519-528 (1998).
17. Lee, C. R., Goldstein, J. A. and Pieper, J. A.: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 12: 251-263 (2002).
18. Scordo, M. G., Aklillu, E., Yasar, U., Dahl, M. L., Spina, E. and Ingelman-Sundberg, M.: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol., 52: 447-450 (2001).
19. Yoon, Y. R., Shon, J. H., Kim, M. K., Lim, Y. C., Lee, H. R., Park, J. Y., Cha, I. J. and Shin, J. G.: Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol., 51: 277-280 (2001).
20. Zhao, F., Loke, C., Rankin, S. C., Guo, J. Y., Lee, H. S., Wu, T. S., Tan, T., Liu, T. C., Lu, W. L., Lim, Y. T., Zhang, Q., Goh, B. C. and Lee, S. C.: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther., 76: 210-219 (2004).
21. Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L. and Rettie, A. E.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med., 352: 2285-2293 (2005).
22. DöAndrea, G., DöAmbrosio, R. L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E. and Margaglione, M.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood, 105: 645-649 (2005).
23. Yuan, H. Y., Chen, J. J., Lee, M. T. M., Wung, J. C., Chen, Y. F., Charng, M. J., Lu, M. J., Hung, C. R., Wei, C. Y., Chen, C. H., Wu, J. Y. and Chen, Y. T.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet., 14: 1745-1751 (2005).
24. Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D. and Deloukas, P.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J., 5: 262-270 (2005).
25. Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T. M., Limdi, N. A., Page, D., Roden, D. M., Wagner, M. J., Caldwell, M. D. and Johnson, J. A.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 360: 753-764 (2009).
26. Erratum in: N. Engl. J. Med., 361: 1613 (2009).
27. Lal, S., Sandanaraj, E., Jada, S. R., Kong, M. C., Lee, L. H., Goh, B. C., Lee, S. C. and Chowbay, B.: Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br. J. Clin. Pharmacol., 65: 260-264 (2008).
28. Sandanaraj, E., Lal, S., Cheung, Y. B., Xiang, X., Kong, M. C., Lee, L. H., Ooi, L. L. and Chowbay, B.: VKORC1 diplotypederived dosing model to explain variability in warfarin dose requirements in Asian patients. Drug Metab. Pharmacokinet., 24: 365-375 (2009).
29. Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T. Y., Eby, C., King, C. R., Brower, A., Schmelzer, J. R., Glurich, I., Vidaillet, H. J., Yale, S. H., Qi Zhang, K., Berg, R. L. and Burmester, J. K.: CYP4F2 genetic variant alters required warfarin dose. Blood, 111: 4106-4112 (2008).
30. Sontag, T. J. and Parker, R. S.: Cytochrome P450 omegahydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J. Biol. Chem., 277: 25290-25296 (2002).
31. Wells, P. S., Majeed, H., Kassem, S., Langlois, N., Gin, B., Clermont, J. and Taljaard, M.: A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thromb. Res., 125: e259-e264 (2010).
32. Borgiani, P., Ciccacci, C., Forte, V., Sirianni, E., Novelli, L., Bramanti, P. and Novelli, G.: CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics, 10: 261-266 (2009).
33. Cen, H. J., Zeng, W. T., Leng, X. Y., Huang, M., Chen, X., Li, J. L., Huang, Z. Y., Bi, H. C., Wang, X. D., He, Y. L., He, F., Zhou, R. N., Zheng, Q. S. and Zhao, L. Z.: CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br. J. Clin. Pharmacol., 70: 234-240 (2010).
34. Harada, T., Ariyoshi, N., Shimura, H., Sato, Y., Yokoyama, I., Takahashi, K., Yamagata, S. I., Imamaki, M., Kobayashi, Y., Ishii, I., Miyazaki, M. and Kitada, M.: Application of Akaike information criterion to evaluate warfarin dosing algorithm. Thromb. Res., 126: 183-190 (2010).
35. Lal, S., Jada, S. R., Xiang, X., Lim, W. T., Lee, E. J. D. and Chowbay, B.: Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clin. Pharmacokinet., 45: 1189-1200 (2006).
36. Stec, D. E., Roman, R. J., Flasch, A. and Rieder, M. J.: Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol. Genomics, 30: 74-81 (2007).
37. McDonald, M. G., Rieder, M. J., Nakano, M., Hsia, C. K. and Rettie, A. E.: CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol., 75: 1337-1346 (2009).
38. Scott, S. A., Khasawneh, R., Peter, I., Kornreich, R. and Desnick, R. J.: Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics, 11: 781-791 (2010).
39. Ross, K. A., Bigham, A. W., Edwards, M., Gozdzik, A., Suarez- Kurtz, G. and Parra, E. J.: Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet, (2010).